After H.C. Wainwright and Oppenheimer gave X4 Pharmaceuticals (NASDAQ: XFOR) a Buy rating last month, the company received another Buy, this time from B.Riley Financial. Analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Thursday at $9.18.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 27.3% and a 50.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $19.20 average price target, an 110.8% upside from current levels. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
Based on X4 Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.45 million. In comparison, last year the company had a GAAP net loss of $17.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
